Milk protein-based nanodelivery systems for the cancer treatment
Source abstract
Abstract
The numerous advantages that nanotechnology can bring to the design of pharmaceutical delivery systems are perhaps nowhere better illustrated than in the area of cancer treatment. These nanostructures not only can improve the anti-proliferative properties of the drugs but also ameliorate the side effects by providing site-specific drug delivery. Furthermore, food-based proteins, due to their biocompatibility and biodegradability, provide a ready-made ingredient as a carrier for various chemotherapeutic agents. The most popular proteins in this field are milk proteins including β-lactoglobulin (β-LG), lactoferrin (LF), and the caseins (CN), all of which have desirable properties to make them ideal for this purpose. Grafting these two approaches, different milk protein-based nanodrugs have been synthesized that show promising potential in providing more targeted delivery of drugs thereby reducing the cytotoxic effects of chemotherapy. In some cases, being encapsulated in these proteins (in nanoscale), the chemotherapeutic agents can be consumed orally while enhancing site-specific delivery. This article reviews various nanodrug delivery systems containing milk proteins, which are designed for cancer treatment. Moreover, their physical and their anti-proliferative characteristics are briefly described. Graphic abstract
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Infant Nutrition and Health · Proteins in Food Systems · Protein Hydrolysis and Bioactive Peptides
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Livney, Y.D.: Milk proteins as vehicles for bioactives. Cur. Opin. Coll. Interface. Sci. 15(1), 73–83 (2010). https://doi.org/10.1016/j.cocis.2009.11.00210.1016/j.cocis.2009.11.002 ↗
2. Zimecki, M., Kruzel, M.L.: Milk-derived proteins and peptides of potential therapeutic and nutritive value. J. Exp. Ther. Oncol. 6(2), 89–106 (2007)
3. Jenness, R.: Biosynthesis and composition of milk. J. Invest. Dermatol. 63(1), 109–118 (1974). https://doi.org/10.1111/1523-1747.ep1267811110.1111/1523-1747.ep12678111 ↗
4. Dalgleish, D.G., Corredig, M.: The structure of the casein micelle of milk and its changes during processing. Ann. Rev. Food. Sci. Technol. 3, 449–467 (2012). https://doi.org/10.1146/annurev-food-022811-10121410.1146/annurev-food-022811-101214 ↗
5. Dickinson, E.: Surface and emulsifying properties of caseins. Res. J. Dairy Sci. 56(3), 471–477 (1989). https://doi.org/10.1017/S002202990002895810.1017/S0022029900028958 ↗
6. Miller, M.J., Witherly, S.A., Clark, D.A.: Casein: a milk protein with diverse biologic consequences. Proc. Soc. Exp. Biol. Med. 195(2), 143–159 (1990). https://doi.org/10.3181/00379727-195-4312910.3181/00379727-195-43129 ↗
7. Glantz, M., Devold, T.G., Vegarud, G.E., Lindmark Månsson, H., Stålhammar, H., Paulsson, M.: Importance of casein micelle size and milk composition for milk gelation. Int. J. Dairy Sci. 93(4), 1444–1451 (2010). https://doi.org/10.3168/jds.2009-285610.3168/jds.2009-2856 ↗
8. Vasbinder, A.J., Rollema, H.S., Bot, A., de Kruif, C.G.: Gelation mechanism of milk as influenced by temperature and pH; studied by the use of transglutaminase cross-linked casein micelles. Int. J. Dairy Sci. 86(5), 1556–1563 (2003). https://doi.org/10.3168/jds.S0022-0302(03)73741-210.3168/jds.S0022-0302(03)73741-2 ↗
9. Hoffman, J.R., Falvo, M.J.: Protein—which is best? J. Sports Sci. Med. 3(3), 118–130 (2004)
10. Madureira, A.R., Pereira, C.I., Gomes, A.M.P., Pintado, M.E., Xavier Malcata, F.: Bovine whey proteins—overview on their main biological properties. Food. Res. Int. 40(10), 1197–1211 (2007). https://doi.org/10.1016/j.foodres.2007.07.00510.1016/j.foodres.2007.07.005 ↗
11. Smithers, G.W.: Whey and whey proteins—from ‘gutter-to-gold.’ Int. Dairy J. 18(7), 695–704 (2008). https://doi.org/10.1016/j.idairyj.2008.03.00810.1016/j.idairyj.2008.03.008 ↗
12. Davoodi, S.H., Shahbazi, R., Esmaeili, S., Sohrabvandi, S., Mortazavian, A., Jazayeri, S., Taslimi, A.: Health-related aspects of milk proteins. Iran. J. Pharm. Res. 15(3), 573–591 (2016)
13. Wu, L.C., Schulman, B.A., Peng, Z.Y., Kim, P.S.: Disulfide determinants of calcium-induced packing in alpha-lactalbumin. Biochemistry 35(3), 859–863 (1996). https://doi.org/10.1021/bi951408p10.1021/bi951408p ↗
14. Layman, D.K., Lonnerdal, B., Fernstrom, J.D.: Applications for alpha-lactalbumin in human nutrition. Nutr. Rev. 76(6), 444–460 (2018). https://doi.org/10.1093/nutrit/nuy00410.1093/nutrit/nuy004 ↗
15. Kamau, S.M., Cheison, S.C., Chen, W., Liu, X.-M., Lu, R.-R.: Alpha-lactalbumin: its production technologies and bioactive peptides. Compr. Rev. Food Sci. Food Saf. 9(2), 197–212 (2010). https://doi.org/10.1111/j.1541-4337.2009.00100.x10.1111/j.1541-4337.2009.00100.x ↗
16. Shafaei, Z., Ghalandari, B., Vaseghi, A., Divsalar, A., Haertle, T., Saboury, A.A., Sawyer, L.: beta-Lactoglobulin: an efficient nanocarrier for advanced delivery systems. Nanomedicine 13(5), 1685–1692 (2017). https://doi.org/10.1016/j.nano.2017.03.00710.1016/j.nano.2017.03.007 ↗
17. Wu, S.Y., Perez, M.D., Puyol, P., Sawyer, L.: beta-Lactoglobulin binds palmitate within its central cavity. J. Biol. Chem. 274(1), 170–174 (1999). https://doi.org/10.1074/jbc.274.1.17010.1074/jbc.274.1.170 ↗
18. Zimet, P., Livney, Y.: Beta-lactoglobulin and its nanocomplexes with pectin as vehicles for ω-3 polyunsaturated fatty acids. Food. Hydrocoll. 23, 1120–1126 (2009). https://doi.org/10.1016/j.foodhyd.2008.10.00810.1016/j.foodhyd.2008.10.008 ↗
19. Dodin, G., Andrieux, M., Kabbani, H.A.: Binding of ellipticine to β-lactoglobulin. Eur. J. Biochem. 193(3), 697–700 (1990). https://doi.org/10.1111/j.1432-1033.1990.tb19389.x10.1111/j.1432-1033.1990.tb19389.x ↗
20. Humphrey, W., Dalke, A., Schulten, K.: VMD: visual molecular dynamics. J. Mol. Graph. 14(1), 33–38 (1996). https://doi.org/10.1016/0263-7855(96)00018-510.1016/0263-7855(96)00018-5 ↗
21. Loch, J., Polit, A., Gorecki, A., Bonarek, P., Kurpiewska, K., Dziedzicka-Wasylewska, M., Lewinski, K.: Two modes of fatty acid binding to bovine beta-lactoglobulin-crystallographic and spectroscopic studies. J. Mol. Recognit. 24(2), 341–349 (2011). https://doi.org/10.1002/jmr.108410.1002/jmr.1084 ↗
22. Valenti, P., Berlutti, F., Conte, M.P., Longhi, C., Seganti, L.: Lactoferrin functions: current status and perspectives. J. Clin. Gastroenterol. 38(6 Suppl), S127-129 (2004). https://doi.org/10.1097/01.mcg.0000128941.46881.3310.1097/01.mcg.0000128941.46881.33 ↗
23. Chierici, R.: Antimicrobial actions of lactoferrin. Adv. Food. Nutr. Res. 10, 247–269 (2001). https://doi.org/10.1007/978-1-4615-0661-4_1210.1007/978-1-4615-0661-4_12 ↗
24. Zhang, Y., Lima, C.F., Rodrigues, L.R.: Anticancer effects of lactoferrin: underlying mechanisms and future trends in cancer therapy. Nutr. Rev. 72(12), 763–773 (2014). https://doi.org/10.1111/nure.1215510.1111/nure.12155 ↗
25. Brock, J.H.: The physiology of lactoferrin. Nanomed. NBM 80(1), 1–6 (2002). https://doi.org/10.1139/o01-21210.1139/o01-212 ↗
26. Lim, L.Y., Koh, P.Y., Somani, S., Al Robaian, M., Karim, R., Yean, Y.L., Mitchell, J., Tate, R.J., Edrada-Ebel, R., Blatchford, D.R., Mullin, M., Dufès, C.: Tumor regression following intravenous administration of lactoferrin- and lactoferricin-bearing dendriplexes. Nanomed. NBM 11(6), 1445–1454 (2015). https://doi.org/10.1016/j.nano.2015.04.00610.1016/j.nano.2015.04.006 ↗
27. Golla, K., Bhaskar, C., Ahmed, F., Kondapi, A.: A target-specific oral formulation of doxorubicin–protein nanoparticles: efficacy and safety in hepatocellular cancer. J. Cancer. 4, 644–652 (2013). https://doi.org/10.7150/jca.709310.7150/jca.7093 ↗
28. Moore, S.A., Anderson, B.F., Groom, C.R., Haridas, M., Baker, E.N.: Three-dimensional structure of diferric bovine lactoferrin at 2.8 A resolution. J. Mol. Biol. 274(2), 222–236 (1997). https://doi.org/10.1006/jmbi.1997.138610.1006/jmbi.1997.1386 ↗
29. Organization, W.H.: Cancer. (2019). https://www.who.int/cancer/resources/keyfacts/en/. Accessed 1 Dec 2019
30. Arruebo, M., Vilaboa, N., Sáez-Gutierrez, B., Lambea, J., Tres, A., Valladares, M., González-Fernández, A.: Assessment of the evolution of cancer treatment therapies. Cancers 3(3), 3279–3330 (2011). https://doi.org/10.3390/cancers303327910.3390/cancers3033279 ↗
31. Nurgali, K., Jagoe, R.T., Abalo, R.: Editorial: adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae? Front. Pharmacol. 9, 245–245 (2018). https://doi.org/10.3389/fphar.2018.0024510.3389/fphar.2018.00245 ↗
32. Chakraborty, S., Rahman, T.: The difficulties in cancer treatment. Ecancermedicalscience 6, ed16 (2012). https://doi.org/10.3332/ecancer.2012.ed1610.3332/ecancer.2012.ed16 ↗
33. Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., Sarkar, S.: Drug resistance in cancer: an overview. Cancers 6(3), 1769–1792 (2014). https://doi.org/10.3390/cancers603176910.3390/cancers6031769 ↗
34. Elshimali, Y.I., Wu, Y., Khaddour, H., Wu, Y., Gradinaru, D., Sukhija, H., Chung, S.S., Vadgama, J.V.: Optimization of cancer treatment through overcoming drug resistance. J. Cancer. Res. Clin. Oncol. 1(2), 107 (2018). https://doi.org/10.31021/jcro.2018110710.31021/jcro.20181107 ↗
35. Schirrmacher, V.: From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment (review). Int. J. Oncol. 54(2), 407–419 (2019). https://doi.org/10.3892/ijo.2018.466110.3892/ijo.2018.4661 ↗
36. Zhang, Q.-Y., Wang, F.-X., Jia, K.-K., Kong, L.-D.: Natural product interventions for chemotherapy and radiotherapy-induced side effects. Front. Pharmacol. 9, 1253–1253 (2018). https://doi.org/10.3389/fphar.2018.0125310.3389/fphar.2018.01253 ↗
37. Jansman, F.G., Sleijfer, D.T., de Graaf, J.C., Coenen, J.L., Brouwers, J.R.: Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer. Drug. Saf. 24(5), 353–367 (2001). https://doi.org/10.2165/00002018-200124050-0000210.2165/00002018-200124050-00002 ↗
38. Wang, X., Zhang, H., Chen, X.: Drug resistance and combating drug resistance in cancer. Cancer. Drug. Res. (2019). https://doi.org/10.20517/cdr.2019.1010.20517/cdr.2019.10 ↗
39. Tran, S., DeGiovanni, P.-J., Piel, B., Rai, P.: Cancer nanomedicine: a review of recent success in drug delivery. CTM 6(1), 44–44 (2017). https://doi.org/10.1186/s40169-017-0175-010.1186/s40169-017-0175-0 ↗
40. Kumar, A., Kaur, H.: Sprayed in-situ synthesis of polyvinyl alcohol/chitosan loaded silver nanocomposite hydrogel for improved antibacterial effects. Int. J. Biol. Macromol. 145, 950–964 (2020). https://doi.org/10.1016/j.ijbiomac.2019.09.18610.1016/j.ijbiomac.2019.09.186 ↗
41. Kumar, A., Behl, T., Chadha, S.: A rationalized and innovative perspective of nanotechnology and nanobiotechnology in chronic wound management. J. Drug. Del. Sci. Technol. 60, 101930 (2020). https://doi.org/10.1016/j.jddst.2020.10193010.1016/j.jddst.2020.101930 ↗
42. Kumar, A., Sanjay, D., Jaiswal, M.: Enhanced intestinal permeability of Tinospora cordifolia extract through nanoemulsion formulation: in-vitro and ex-vivo studies. J. Nanopharm. Drug. Deliv. 2, 1–10 (2014)10.1166/jnd.2014.1036 ↗
43. Chadha, S., Kumar, A., Srivastava, S.A., Behl, T., Ranjan, R.: Inulin as a delivery vehicle for targeting colon-specific cancer. Curr. Drug Deliv. 17(8), 651–674 (2020). https://doi.org/10.2174/156720181766620052713371910.2174/1567201817666200527133719 ↗
44. Arun, K., Tapan, B., Toshi, U., Swati, C.: Synthesis of nanostructured lipid carriers loaded chitosan/carbopol hybrid nanocomposite gel for oral delivery of artemether and curcumin. Pharm. Nanotechnol. 8(5), 418–432 (2020). https://doi.org/10.2174/221173850866620090711044410.2174/2211738508666200907110444 ↗
45. Calzoni, E., Cesaretti, A., Polchi, A., Di Michele, A., Tancini, B., Emiliani, C.: Biocompatible polymer nanoparticles for drug delivery applications in cancer and neurodegenerative disorder therapies. J. Funct. Biomater. 10(1), 4 (2019). https://doi.org/10.3390/jfb1001000410.3390/jfb10010004 ↗
46. Jadia, R., Scandore, C., Rai, P.: Nanoparticles for effective combination therapy of cancer. Int. J. Nanotechnol. Nanomed. (2016). https://doi.org/10.33140/IJNN/01/01/0000310.33140/IJNN/01/01/00003 ↗
47. Elzoghby, A.O., Samy, W.M., Elgindy, N.A.: Protein-based nanocarriers as promising drug and gene delivery systems. J. Control. Release 161(1), 38–49 (2012). https://doi.org/10.1016/j.jconrel.2012.04.03610.1016/j.jconrel.2012.04.036 ↗
48. Chen, L., Remondetto, G.E., Subirade, M.: Food protein-based materials as nutraceutical delivery systems. Trends. Food. Sci. Technol. 17(5), 272–283 (2006). https://doi.org/10.1016/j.tifs.2005.12.01110.1016/j.tifs.2005.12.011 ↗
49. Shapira, A., Assaraf, Y.G., Livney, Y.D.: Beta-casein nanovehicles for oral delivery of chemotherapeutic drugs. Nanomedicine 6(1), 119–126 (2010). https://doi.org/10.1016/j.nano.2009.06.00610.1016/j.nano.2009.06.006 ↗
50. Bijari, N., Ghobadi, S., Derakhshandeh, K.: β-Lactoglobulin-irinotecan inclusion complex as a new targeted nanocarrier for colorectal cancer cells. Res. Pharm. Sci. 14(3), 216–227 (2019). https://doi.org/10.4103/1735-5362.25848810.4103/1735-5362.258488 ↗
51. Farokhzad, O.C., Langer, R.: Impact of nanotechnology on drug delivery. ACS Nano 3(1), 16–20 (2009). https://doi.org/10.1021/nn900002m10.1021/nn900002m ↗
52. Burgess, P., Hutt, P.B., Farokhzad, O.C., Langer, R., Minick, S., Zale, S.: On firm ground: IP protection of therapeutic nanoparticles. Biotechnol. Tech. 28(12), 1267–1270 (2010). https://doi.org/10.1038/nbt.172510.1038/nbt.1725 ↗
53. Choe, T.B., Park, I.C., Hong, S.I.: Enhancement of cationic liposome-mediated transfection by lactoferrin. Biotechnol. Tech. 12(7), 577–581 (1998). https://doi.org/10.1023/A:100883611099610.1023/A:1008836110996 ↗
54. Salatin, S., Barar, J., Barzegar-Jalali, M., Adibkia, K., Kiafar, F., Jelvehgari, M.: Development of a nanoprecipitation method for the entrapment of a very water soluble drug into Eudragit RL nanoparticles. Res. Pharm. Sci. 12(1), 1–14 (2017). https://doi.org/10.4103/1735-5362.19904110.4103/1735-5362.199041 ↗
55. Yadav, K.S., Sawant, K.K.: Modified nanoprecipitation method for preparation of cytarabine-loaded PLGA nanoparticles. AAPS Pharm. Sci. Tech. 11(3), 1456–1465 (2010). https://doi.org/10.1208/s12249-010-9519-410.1208/s12249-010-9519-4 ↗
56. Abdelmoneem, M.A., Mahmoud, M., Zaky, A., Helmy, M.W., Sallam, M., Fang, J.Y., Elkhodairy, K.A., Elzoghby, A.O.: Decorating protein nanospheres with lactoferrin enhances oral COX-2 inhibitor/herbal therapy of hepatocellular carcinoma. Nanomedicine 13(19), 2377–2395 (2018). https://doi.org/10.2217/nnm-2018-013410.2217/nnm-2018-0134 ↗
57. Kanwar, J., Samarasinghe, R., Shegal, R., Kanwar, R.: Nano-lactoferrin in diagnostic, imaging and targeted delivery for cancer and infectious diseases. J. Cancer. Sci. Ther. 4, 31–42 (2012). https://doi.org/10.4172/1948-5956.100010710.4172/1948-5956.1000107 ↗
58. Pang, Z., Feng, L., Hua, R., Chen, J., Gao, H., Pan, S., Jiang, X., Zhang, P.: Lactoferrin-conjugated biodegradable polymersome holding doxorubicin and tetrandrine for chemotherapy of glioma rats. Mol. Pharm. 7(6), 1995–2005 (2010). https://doi.org/10.1021/mp100277h10.1021/mp100277h ↗
59. Chen, H., Tang, L., Qin, Y., Yin, Y., Tang, J., Tang, W., Sun, X., Zhang, Z., Liu, J., He, Q.: Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery. Eur. J. Pharm. Sci. 40(2), 94–102 (2010). https://doi.org/10.1016/j.ejps.2010.03.00710.1016/j.ejps.2010.03.007 ↗
60. Chen, H., Qin, Y., Zhang, Q., Jiang, W., Tang, L., Liu, J., He, Q.: Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas. Eur. J. Pharm. Sci. 44(1–2), 164–173 (2011). https://doi.org/10.1016/j.ejps.2011.07.00710.1016/j.ejps.2011.07.007 ↗
61. Kanwar, J.R., Mahidhara, G., Kanwar, R.K.: Novel alginate-enclosed chitosan-calcium phosphate-loaded iron-saturated bovine lactoferrin nanocarriers for oral delivery in colon cancer therapy. Nanomedicine 7(10), 1521–1550 (2012). https://doi.org/10.2217/nnm.12.2910.2217/nnm.12.29 ↗
62. Mahidhara, G., Kanwar, R.K., Roy, K., Kanwar, J.R.: Oral administration of iron-saturated bovine lactoferrin-loaded ceramic nanocapsules for breast cancer therapy and influence on iron and calcium metabolism. Int. J. Nanomed. 10, 4081–4098 (2015). https://doi.org/10.2147/IJN.S7587710.2147/IJN.S75877 ↗
63. Kanwar, J.R., Mahidhara, G., Roy, K., Sasidharan, S., Krishnakumar, S., Prasad, N., Sehgal, R., Kanwar, R.K.: Fe-bLf nanoformulation targets survivin to kill colon cancer stem cells and maintains absorption of iron, calcium and zinc. Nanomedicine 10(1), 35–55 (2015). https://doi.org/10.2217/nnm.14.13210.2217/nnm.14.132 ↗
64. Abdelmoneem, M.A., Elnaggar, M.A., Hammady, R.S., Kamel, S.M., Helmy, M.W., Abdulkader, M.A., Zaky, A., Fang, J.Y., Elkhodairy, K.A., Elzoghby, A.O.: Dual-targeted lactoferrin shell-oily core nanocapsules for synergistic targeted/herbal therapy of hepatocellular carcinoma. ACS Appl. Mat. Interfaces 11(30), 26731–26744 (2019). https://doi.org/10.1021/acsami.9b1016410.1021/acsami.9b10164 ↗
65. Sabra, S.A., Elzoghby, A.O., Sheweita, S.A., Haroun, M., Helmy, M.W., Eldemellawy, M.A., Xia, Y., Goodale, D., Allan, A.L., Rohani, S.: Self-assembled amphiphilic zein-lactoferrin micelles for tumor targeted co-delivery of rapamycin and wogonin to breast cancer. Eur J Pharm Biopharm. 128, 156–169 (2018). https://doi.org/10.1016/j.ejpb.2018.04.02310.1016/j.ejpb.2018.04.023 ↗
66. Ko, S., Gunasekaran, S.: Preparation of sub-100-nm beta-lactoglobulin (BLG) nanoparticles. J. Microencapsul. 23(8), 887–898 (2006). https://doi.org/10.1080/0265204060103514310.1080/02652040601035143 ↗
67. Sahoo, B.K., Ghosh, K.S., Dasgupta, S.: Investigating the binding of curcumin derivatives to bovine serum albumin. Biophys. Chem. 132(2), 81–88 (2008). https://doi.org/10.1016/j.bpc.2007.10.00710.1016/j.bpc.2007.10.007 ↗
68. Barik, A., Mishra, B., Kunwar, A., Indira Priyadarsini, K.: Interaction of curcumin with human serum albumin: thermodynamic properties, fluorescence energy transfer and denaturation effects. Chem. Phys. Lett. 436(1), 239–243 (2007). https://doi.org/10.1016/j.cplett.2007.01.00610.1016/j.cplett.2007.01.006 ↗
69. Mohammadi, F., Bordbar, A.K., Divsalar, A., Mohammadi, K., Saboury, A.A.: Interaction of curcumin and diacetylcurcumin with the lipocalin member beta-lactoglobulin. Protein J. 28(3–4), 117–123 (2009). https://doi.org/10.1007/s10930-009-9171-610.1007/s10930-009-9171-6 ↗
70. Divsalar, A., Zhila, I., Saboury, A.A., Nabiuni, M., Razmi, M., Mansuri-Torshizi, H.: Cytotoxic and spectroscopic studies on binding of a new synthesized bipyridine ethyl dithiocarbamate Pt(II) nitrate complex to the milk carrier protein of BLG. J. Iran. Chem. Soc. 10(5), 951–959 (2013). https://doi.org/10.1007/s13738-013-0232-610.1007/s13738-013-0232-6 ↗
71. Sneharani, A.H., Karakkat, J.V., Singh, S.A., Rao, A.G.: Interaction of curcumin with beta-lactoglobulin-stability, spectroscopic analysis, and molecular modeling of the complex. J. Agric. Food Chem. 58(20), 11130–11139 (2010). https://doi.org/10.1021/jf102826q10.1021/jf102826q ↗
72. Teng, Z., Li, Y., Wang, Q.: Insight into curcumin-loaded β-lactoglobulin nanoparticles: incorporation, particle disintegration, and releasing profiles. J. Agric. Food Chem. 62(35), 8837–8847 (2014). https://doi.org/10.1021/jf503199g10.1021/jf503199g ↗
73. Li, M., Cui, J., Ngadi, M.O., Ma, Y.: Absorption mechanism of whey-protein-delivered curcumin using Caco-2 cell monolayers. Food Chem. 180, 48–54 (2015). https://doi.org/10.1016/j.foodchem.2015.01.13210.1016/j.foodchem.2015.01.132 ↗
74. Aditya, N.P., Yang, H., Kim, S., Ko, S.: Fabrication of amorphous curcumin nanosuspensions using β-lactoglobulin to enhance solubility, stability, and bioavailability. Coll. Surf. B Biointerfaces 127, 114–121 (2015). https://doi.org/10.1016/j.colsurfb.2015.01.02710.1016/j.colsurfb.2015.01.027 ↗
75. Divsalar, A., Saboury, A., Mansouri-Torshizi, H., Moosavi-Movahedi, A.: Binding properties of a new anti-tumor component (2,2′-bipyridin octylglycinato Pd(II) nitrate) with bovine β-lactoglobulin-A and -B. J. Biomol. Struct. Dyn. 25, 173–182 (2007). https://doi.org/10.1080/07391102.2007.1050716610.1080/07391102.2007.10507166 ↗
76. Abazari, O., Divsalar, A., Ghobadi, R.: Inhibitory effects of oxali-platin as a chemotherapeutic drug on the function and structure of bovine liver catalase. J. Biomol. Struct. Dyn. 38(2), 609–615 (2020). https://doi.org/10.1080/07391102.2019.158108810.1080/07391102.2019.1581088 ↗
77. Mohammadgholi, A., Leilabadi-Asl, A., Divsalar, A., Eslami-Moghadam, M.: Multi-spectroscopic studies of the interaction of new synthesized platin complex with human carrier protein of serum albumin. J. Biomol. Struct. Dyn. 39, 1–6 (2020). https://doi.org/10.1080/07391102.2020.174569010.1080/07391102.2020.1745690 ↗
78. Divsalar, A., Saboury, A.A., Mansouri-Torshizi, H., Moghaddam, M.I., Ahmad, F., Hakimelahi, G.H.: Comparative studies on the interaction between bovine beta-lacto-globulin type A and B and a new designed Pd(II) complex with anti-tumor activity at different temperatures. J. Biomol. Struct. Dyn. 26(5), 587–597 (2009)10.1080/07391102.2009.10507274 ↗
79. Divsalar, A., Saboury, A.A., Yousefi, R., Moosavi-Movahedi, A.A., Mansoori-Torshizi, H.: Spectroscopic and cytotoxic studies of the novel designed palladium(II) complexes: β-lactoglobulin and K562 as the targets. Int. J. Biol. Macromol. 40(4), 381–386 (2007). https://doi.org/10.1016/j.ijbiomac.2006.09.01510.1016/j.ijbiomac.2006.09.015 ↗
80. Divsalar, A., Saboury, A.A., Mansoori-Torshizi, H., Moosavi-Movahedi, A.A.: Binding properties of a new anti-tumor component (2,2’-bipyridin octylglycinato Pd(II) nitrate) with bovine beta-lactoglobulin-A and -B. J. Biomol. Struct. Dyn. 25(2), 173–182 (2007). https://doi.org/10.1080/07391102.2007.1050716610.1080/07391102.2007.10507166 ↗
81. Divsalar, A., Saboury, A.A., Mansoori-Torshizi, H., Moghaddam, M.I., Ahmad, F., Hakimelahi, G.H.: Comparative studies on the interaction between bovine β-lacto-globulin type A and B and a new designed Pd(II) complex with anti-tumor activity at different temperatures. J. Biomol. Struct. Dyn. 26(5), 587–597 (2009). https://doi.org/10.1080/07391102.2009.1050727410.1080/07391102.2009.10507274 ↗
82. Leilabadi-Asl, A., Divsalar, A., Saboury, A.A., Parivar, K.: Probing the interaction of two chemotherapeutic drugs of oxali-palladium and 5-fluorouracil simultaneously with milk carrier protein of β-lactoglobulin. J. Biomol. Struct. Dyn. 112, 422–432 (2018). https://doi.org/10.1016/j.ijbiomac.2018.01.06710.1016/j.ijbiomac.2018.01.067 ↗
83. Ghalandari, B., Divsalar, A., Saboury, A.A., Haertlé, T., Parivar, K., Bazl, R., Eslami-Moghadam, M., Amanlou, M.: Spectroscopic and theoretical investigation of oxali–palladium interactions with β-lactoglobulin. Spectrochim. Acta. A Mol. Biomol. Spectrosc. 118, 1038–1046 (2014). https://doi.org/10.1016/j.saa.2013.09.12610.1016/j.saa.2013.09.126 ↗
84. Ghalandari, B., Divsalar, A., Saboury, A.A., Parivar, K.: The new insight into oral drug delivery system based on metal drugs in colon cancer therapy through beta-lactoglobulin/oxali-palladium nanocapsules. J. Photochem. Photobiol. B. 140, 255–265 (2014). https://doi.org/10.1016/j.jphotobiol.2014.08.00310.1016/j.jphotobiol.2014.08.003 ↗
85. Divsalar, A., Saboury, A.A., Mansoori-Torshizi, H., Ahmad, F.: Design, synthesis, and biological evaluation of a new palladium(II) complex: β-lactoglobulin and K562 as targets. J. Phys. Chem. B. 114(10), 3639–3647 (2010). https://doi.org/10.1021/jp909143b10.1021/jp909143b ↗
86. Divsalar, A., Barzegar, L., Behbehani, G.R.: Thermal study of a newly synthesized Cu(II) complex binding to bovine. J. Chem. 2013, 453056 (2013). https://doi.org/10.1155/2013/45305610.1155/2013/453056 ↗
87. Zheng, G., Liu, H., Zhu, Z., Zheng, J., Liu, A.: Selenium modification of beta-lactoglobulin (beta-Lg) and its biological activity. Food. Chem. 204, 246–251 (2016). https://doi.org/10.1016/j.foodchem.2016.01.01610.1016/j.foodchem.2016.01.016 ↗
88. Zhao, Y., Liu, Y., Wang, W., Wu, D., Shi, J., Liu, A.: Apoptosis and autophagy induction of seleno-β-lactoglobulin (Se-β-Lg) on hepatocellular carcinoma cells lines. J. Funct. Foods. 49, 412–423 (2018). https://doi.org/10.1016/j.jff.2018.09.01110.1016/j.jff.2018.09.011 ↗
89. Sun, S.-J., Feng, Y.-Y., Zhang, Y., Ji, H.-Y., Yu, J., Liu, A.-J.: Antitumor and immunoregulatory activities of seleno-β-lactoglobulin on S180 tumor-bearing mice. Molecules 23, 46 (2017). https://doi.org/10.3390/molecules2301004610.3390/molecules23010046 ↗
90. Zheng, G.-Q., Ji, H.-Y., Zhang, S.-J., Yu, J., Liu, A.-J.: Selenious-β-lactoglobulin induces the apoptosis of human lung cancer A549 cells via an intrinsic mitochondrial pathway. Cytotechnology 70, 1551–1563 (2018). https://doi.org/10.1007/s10616-018-0248-y10.1007/s10616-018-0248-y ↗
91. Yu, J., Dong, X., Wang, L., Ji, H., Liu, A.: Antitumor effects of seleno-beta-lactoglobulin (Se-beta-Lg) against human gastric cancer MGC-803 cells. Eur. J. Pharmacol. 833, 109–115 (2018). https://doi.org/10.1016/j.ejphar.2018.05.04210.1016/j.ejphar.2018.05.042 ↗
92. Zhang, J., Teng, Z., Yuan, Y., Zeng, Q.Z., Lou, Z., Lee, S.H., Wang, Q.: Development, physicochemical characterization and cytotoxicity of selenium nanoparticles stabilized by beta-lactoglobulin. Int. J. Biol. Macromol. 107(Pt B), 1406–1413 (2018). https://doi.org/10.1016/j.ijbiomac.2017.09.11710.1016/j.ijbiomac.2017.09.117 ↗
93. Brauckmann, C., Wehe, C.A., Kieshauer, M., Lanvers-Kaminsky, C., Sperling, M., Karst, U.: The interaction of platinum-based drugs with native biologically relevant proteins. Anal. Bioanal. Chem. 405(6), 1855–1864 (2013). https://doi.org/10.1007/s00216-012-6410-z10.1007/s00216-012-6410-z ↗
94. Ghalandari, B., Divsalar, A., Eslami-Moghadam, M., Saboury, A.A., Haertle, T., Amanlou, M., Parivar, K.: Probing of the interaction between beta-lactoglobulin and the anticancer drug oxaliplatin. Appl. Biochem. Biotechnol. 175(2), 974–987 (2015). https://doi.org/10.1007/s12010-014-1341-010.1007/s12010-014-1341-0 ↗
95. Brauckmann, C., Faber, H., Lanvers-Kaminsky, C., Sperling, M., Karst, U.: Influence of cimetidine and its metabolites on cisplatin—investigation of adduct formation by means of electrochemistry/liquid chromatography/electrospray mass spectrometry. J. Chromatogr. A 1279, 49–57 (2013). https://doi.org/10.1016/j.chroma.2012.12.06910.1016/j.chroma.2012.12.069 ↗
96. Izadi, Z., Divsalar, A., Saboury, A.A., Sawyer, L.: beta-Lactoglobulin-pectin nanoparticle-based oral drug delivery system for potential treatment of colon cancer. Chem Biol Drug Des. 88(2), 209–216 (2016). https://doi.org/10.1111/cbdd.1274810.1111/cbdd.12748 ↗
97. Jones, O., Decker, E.A., McClements, D.J.: Thermal analysis of β-lactoglobulin complexes with pectins or carrageenan for production of stable biopolymer particles. Food Hydrocoll. 24(2/3), 239–248 (2010). https://doi.org/10.1016/j.foodhyd.2009.10.00110.1016/j.foodhyd.2009.10.001 ↗
98. Bijari, N., Ghobadi, S., Derakhshandeh, K.: Irinotecan binds to the internal cavity of beta-lactoglobulin: a multi-spectroscopic and computational investigation. Pharm. Res. 139, 109–115 (2017). https://doi.org/10.1016/j.jpba.2017.02.05010.1016/j.jpba.2017.02.050 ↗
99. Langer, K., Balthasar, S., Vogel, V., Dinauer, N., von Briesen, H., Schubert, D.: Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int. J. Pharm. 257(1–2), 169–180 (2003). https://doi.org/10.1016/s0378-5173(03)00134-010.1016/s0378-5173(03)00134-0 ↗
100. Jahanban-Esfahlan, A., Dastmalchi, S., Davaran, S.: A simple improved desolvation method for the rapid preparation of albumin nanoparticles. Int. J. Biol. Macromol. 91, 703–709 (2016). https://doi.org/10.1016/j.ijbiomac.2016.05.03210.1016/j.ijbiomac.2016.05.032 ↗